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Abstarct: 
Sustained release Ketoprofen matrix tablets were prepared by direct compression method. The nature of the 
polymer influences the physical and release characteristics of the matrix tablet. The hydrophobic polymer, Ethyl 
cellulose has retarded the drug release from the tablet and the hydrophilic polymer, HPMC (15 cps) has release the 
drug. While making the combination of both hydrophilic and hydrophobic polymers i.e HPMC and Ethylcellulose 
with optimized ratio (F7) leads to sustained release of drug from matrix tablet for 12 hours was observed 
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INTRODUCTION: 
Conventional medication systems that require multi-
dose therapy are not without problems. With a view 
to overcoming these problems, the current trend in 
pharmaceutical research is to design and develop new 
formulations, thereby enhancing the therapeutic 
efficacy of existing drugs. Moreover, the impetus for 
research into drug delivery can be attributed to the 
exorbitant cost and large development period 
involved in ‘new drug development’ with 
concomitant recognition of the therapeutic 
advantages of Controlled / Sustained drug delivery. 
Sustained Release systems include any drug delivery 
system that achieves slow release of drug over an 
extended period of time. 
 
Ketoprofen (KP) is a poorly water-soluble non-
steroidal anti-inflammatory, antipyretic and analgesic 
drug, frequently used for the treatment of rheumatoid 
arthritis, osteoarthritis, anklylosing spondylitis, a 
variety of other acute and chronic musculoskeletal 
disorders and mild to moderate pain is a potent non-
steroidal anti-inflammatory drug that inhibits 
prostaglandin synthetase cyclooxygenase. Its oral 
administration is associated with a high risk of 
adverse effects such as irritation, ulceration of the 
gastrointestinal tract, oedema, dizziness, and peptic 
ulceration when taken orally for a prolonged period. 
These attributes make KP a good candidate for 
controlled release dosage forms. Microspheres are 
one of the multiparticulate drug delivery systems and 
are prepared to obtain prolonged drug delivery, 
improve bioavailability or stability and target drug to 
specific sites. They have played a vital role in the 
development of controlled/sustained release drug 
delivery systems. The Eudragits are a family of 
polymers based on acrylic and methacrylic acids 
suitable for use in orally administered drug delivery 
systems. They have been used in the 
microencapsulation of drugs. Some dissolve rapidly 
at clearly defined pH values, whereas two grades, 
Eudragit ® RL and RS, are insoluble in aqueous 
media water and digestive juices, but swell and are 
permeable, which means that the drugs can be 
released by diffusion. Therefore, the permeability of 
drug through Eudragit RS and/or RL is independent 
on the pH of the digestive tract Eudragit®RS100 is a 
water-insoluble polymer that is widely used as a wall 
material for sustained release microspheres due to its 
biocompatibility, good stability, easy fabrication and 
low cost. 
 
EXPERIMENTAL METHOD: 
Materials  
Ketoprofen, Eudragit RL 100, Ethylcellulose, 
Hydroxyl propyl methyl cellulose 15 cps, Lactose, 
Micro crystalline cellulose, Starch, Magnesium 
stearate, Talc all the chemicals used were lab grade. 
Tablets of Ketoprofen were prepared by direct 
compression. Ketoprofen and excipients are weighed 
accurately and passed through 60# mesh sieve 
separately. The drug and polymers was mixed by 
small portion of both each time and blending it to get 
a uniform mixture and kept aside. Then the 
ingredients were added, mixed in geometrical order 
and are compressed for tablets. 
 
Table.1 Formulation of Ketoprofen sustained release tablets 
 
 
 
 
 
 
 
 
 
Ingredients 
 
F1 
(mg) 
 
F2 
(mg) 
 
F3 
(mg) 
 
F4 
(mg) 
 
F5 
(mg) 
 
F6 
(mg) 
 
F7 
(mg) 
 
F8 
(mg) 
Ketoprofen 100 100 100 100 100 100 100 100 
HPMC 15 cps 50 50 70 70 50 50 70 70 
Eudragit RL 100 20 40 20 40     
Ethyl cellulose  - - - - 20 40 20 40 
Lactose 260 - 240 - 260 - 240 - 
Microcrystalline cellulose - 240 - 220 - 240 - 220 
Starch 50 50 50 50 50 50 50 50 
Magnesium stearate 10 10 10 10 10 10 10 10 
Talc 10 10 10 10 10 10 10 10 
Total (mg) 500 500 500 500 500 500 500 500 
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Pre-compression evaluation: 
Micromeritic properties 
a) Angle of repose : 
The angle of repose of powder was determined by the 
fixed funnel method. The accurately weighed powder 
was taken in a funnel. The height (h) of the funnel 
was adjusted in such a way that the tip of the funnel 
just touches the apex of the heap of the powder. The 
powder was allowed to flow through funnel freely 
onto the surface. The diameter of the powder cone 
was measured and angle of repose was calculated 
using the following equation. 
 tan θ = h/r -------------- (1)  
Therefore, θ = tan-1h/r  
Where, θ = angle of repose, 
 h = height of the pile,  
r = radius of the pile base.  
 
b) Bulk densidty:  
Both loose bulk density (LBD) or bulk density and 
tapped bulk density (TBD) were determined. Powder 
from each formulation, previously lightly shaken to 
break  any agglomerates formed was introduced into 
a 10 ml measuring cylinder. After the initial volume 
was observed, the cylinder was allowed to fall under 
its own weight onto a hard surface from the height of 
2.5 cm at 2 sec intervals. The tapping was continued 
until no further change in volume was noted.  
Bulk density is calculated by using formula  
Bulk density = weight of powder / bulk volume of 
powder  
Tapped density = weight of powder / tapped volume 
of powder 
 
 c) Compressibility index and husner’s ratio: 
The compressibility index has been proposed as an 
indirect measure of bulk density, size and shape, 
surface area, moisture content, and cohesiveness of 
materials because all of these can influence the 
observed compressibility index. The compressibility 
index and the hausner‟s ratio are determined by 
measuring both the bulk volume and the tapped 
volume of a powder.  
Compressibility Index (%) = (TBD – LBD) × 100 / 
TBD  
Hausner’s ratio = TBD / LBD  
Where, LBD = weight of the powder/volume of the 
packing,  
TBD = weight of the Powder / tapped volume of the 
packing.  
 
Post-compression evaluation 
Physical appearance: 
The tablets are visually observed for capping, 
chipping, lamination and changes in colour.  
 
Tablet thickness: 
The thicknesses of the tablets can be determined by 
using Vernier calliper. Five tablets are required, and 
average values are calculated. Variation in tablet may 
cause problems in counting and packaging. Tablet 
thickness should be controlled within a ±5% of a 
standard value. 
Hardness: 
Hardness testing determines that tablet was able to 
withstand mechanical shocks while handling. The 
hardness of the tablets is determined by using 
Monsanto hardness tester. It is expressed in kg/cm2. 
10 tablets are randomly picked and hardness of the 
tablets is determined. 
 
Weight variation: 
20 tablets are selected randomly and weighed 
individually to check for weight variation. 
 
Friability: 
20 tablets from each batch are selected randomly and 
weight. The friability of tablets is determined by 
using Roche Friabilator for 100 revolutions. The 
friabilator is operated at 25 rpm for 4 min. The tablets 
are subject to combine effect of abrasion and shock in 
a plastic chamber and dropping a tablet at height of 
6 in. in each revolution. The tablets were removed, 
de-dusted and weighed again. It is expressed in 
percentage (%). % Friability of tablets less than 1% is 
considered acceptable. The % friability was then 
calculated by using formula: 
  
 
 
In vitro dissolution study: 
Rotating basket (USP method I) was adopted for the 
dissolution study of all tablet formulations. 
Ketoprofen dissolution media would be pH 7.4 
phosphate buffers. The pH value of 7.4 was chosen in 
order to achieve a maximum drug release from the 
tablet, since the drug is poorly soluble at low pH 
conditions. Temperature of dissolution medium 
should maintain at 37 ± 0.5 °C and the rotating speed 
adjusted to 100 rpm. Samples of 5 ml are taken at 
time intervals of 0.5, 1, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 8.0 
10.0, 12.0, 18.0 and 24 h and filtered using filter 
paper of 0.45 μm. Then all samples should be 
observed spectrophotometrically (UV–Visible 
spectrophotometer evolution 60, Thermo Scientific) 
with wavelength of 260 nm and note their respective 
absorbance. Then, the per cent release is calculated 
for all tablets from the standard curves. The 
dissolution experiments were conducted in triplicate. 
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RESULTS AND DISCUSSION: 
Table  2:  standard graph of Ketoprofen 
 
S.NO CONCENTRATION  (µg/ml) ABSORBANCE                 (at 260 nm) 
1 10 0.221 
2 20 0.422 
3 30 0.647 
4 40 0.832 
5 50 1.102 
 
 
                                          Fig 1: Calibration Curve of Ketoprofen 
Preformulation studies of blend: 
Evaluation of mixed blend of drug and excipients  
Table 3:   Preformulation  evaluation 
 
Formula Angle of 
repose (θ) 
Bulk density 
(gm/cm3) 
Tapped 
density 
(gm/cm3) 
Compressibility 
index (I) 
Hausner,s 
ratio 
F1 30.13 0.43 0.48 10.41 1.11 
F2 27.46 0.46 0.52 11.53 1.13 
F3 26.13 0.42 0.48 12.50 1.14 
F4 28.21 0.38 0.45 15.55 1.18 
F5 25.22 0.46 0.56 14.28 1.16 
F6 28.57 0.48 0.55 12.72 1.14 
F7 26.43 0.39 0.43 11.30 1.10 
F8 28.26 0.45 0.51 11.76 1.13 
 
Evaluation of Ketoprofen sustained release tablets 
The physical parameters like weight variation, hardness, thickness, drug content of the prepared tablets were within 
the pharmacopoeia limits. The results of the test were tabulated with the standard deviation  
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Table  4:  Evaluation of tablets 
Formulation 
Weight 
variation 
Hardness 
(kg/cm2) 
Thickness 
(mm) 
Friability (%) 
Content Uniformity 
(mg/tab) 
F1 499±0.7 4.0±0.13 3.65±0.02 0.7±0.01 99.00±1.55 
F2 500±0.5 5.4±0.15 3.48±0.03 0.5±0.02 101.00±2.20 
F3 499±0.6 4.6±0.13 3.42±0.02 0..6±0.01 99.55±1.10 
F4 500±0.8 4.3±0.14 3.75±0.04 0.8±0.03 101.00±2.20 
F5 499±0.7 4.8±0.16 3.80±0.03 0.6±0.01 99.75±0.55 
F6 500±0.6 5.0±0.15 3.84±0.02 0.6±0.03 102.00±2.20 
F7 500±0.5 4.5±0.15 3.66±0.03 0.7±0.02 99.50±3.00 
F8 498±0.6 5.0±0.14 3.88±0.02 0.5±0.01 99.23±1.13 
 
Table 5:   Drug release profile of marketed product, F1, F2, F3, F4 
 
 
Time 
(hrs) 
 
Marketed 
product 
% drug 
Release 
F1 Cumulative 
% drug 
release 
F2 
Cumulative 
% drug 
Release 
F3 
Cumulative 
% drug 
Release 
F4 
Cumulative 
% drug 
Release 
0 
0 
0 0 0 0 
2 13.5 42.72 49.13 23.93 30.78 
4 65.5 63.15 68.52 47.73 52.36 
6 78.4 84.72 88.34 67.34 76.92 
8 89.68 94.85 96.58 86.26 87.48 
10 96.58 - - 96.30 99.50 
12 - - - - - 
 
 
 
 
Fig 2: Drug release profile of innovator and F1, F2, F3, F4 Formulations 
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Drug release profiles of F5, F6, F7, F8, Formulations: 
 
Table  6:   Drug release profile   of innovator F5, F6, F7, F8. 
 
 
Time 
(hrs) 
 
Marketed 
% drug 
Release 
F5 Cumulative 
% drug 
Release 
F6 
Cumulative 
% drug 
release 
F7 
Cumulative 
% drug 
Release 
F8 
Cumulative 
% drug 
Release 
0 0 0 0 0 0 
2 13.5 32.72 35.67 20.96 17.85 
4 65.5 51.87 51.87 47.20 42.72 
6 78.4 73.24 73.24 65.60 63.15 
8 89.68 88.69 89.59 71.20 78.12 
10 96.58 98.26 97.68 94.90 92.58 
12 - - - 98.9 93.78 
 
The above figure shows the In vitro release profiles of Ketoprofen sustained release tablets of formulations F5, F6, 
F7, F8 effect of HPMC (15 cps) and ethyl cellulose polymer on the release profile of Ketoprofen was studied. The 
formulation F7, F8 combination of HPMC (15 cps) and ethyl cellulose showed 98.9% and 93.78% respectively for 
12hr. The formulation F7 showed 98.9% up to 12hrs. 
 
 
 
Fig 3: Drug release profile of marketed product (KETOFEN) and F5, F6, F7, F8 Formulations 
 
Fig 4: Drug release profile of marketed product (KETOFEN) and   Optimized (F7) 
Formulation 
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SUMMARY AND CONCLUSION: 
Summary: 
The purpose of the present study was formulation 
development and evaluation of Ketoprofen sustained 
release matrix tablets of strength 100 mg.  Direct 
compression technique was chosen to develop a 
finished pharmaceutical product. Various 
formulations (F1-F8) were taken. In these trials, drug: 
excipient ratio was varied and the effect of diluents, 
and various polymers  like Eudragit RL 100, HPMC 
15 cps, and ethyl cellulose on the performance tablets 
was studied. All the formulations showed angle of 
repose below 300 that mean they show free flowing 
property. All the formulation has hausner’s ratio 
between the 1.10 to1.5. It indicates all the 
formulation show better flow property. The physical 
parameters like weight variation, hardness, thickness, 
drug content of the prepared tablets were within the 
pharmacopoeial limits. The total weight of each 
formulation was maintained constant. The weight 
variation of tablets was within the limit of 7.5% as 
specified. , Hardness ranges 4.3 to 5.4 kg/cm2 and the 
friability loss of less than 1% in weight is generally 
acceptable. Content uniformity 99.55% to 101 % 
mg/tab was found.Among all formulation F7 showed 
in-vitro drug release 98.9% for 12hrs. And which is 
showed better release than marketed product 
(KETOFEN) hence considered as most promising 
preparation.  
 
Conclusion: 
The Sustained release Ketoprofen matrix tablets were 
prepared by direct compression method. The nature 
of the polymer influences the physical and release 
characteristics of the matrix tablet. The hydrophobic 
polymer, Ethyl cellulose has retarded the drug release 
from the tablet and the hydrophilic polymer, HPMC 
(15 cps) has release the drug. While making the 
combination of both hydrophilic and hydrophobic 
polymers i.e HPMC and Ethylcellulose with 
optimized ratio (F7) leads to sustained release of drug 
from matrix tablet for 12 hours was observed. 
REFERENCES: 
1. A.K.Srivastava, Saurabh wadhwa, B.mishra, “oral 
sustained delivery of Atenolol from floating matrix 
tablets - formulation and in vitro evaluation.” Drug 
development and industrial pharmacy, 2005;31: (4-
5), pg 367-374. 
2.Ansel HC, Popovich NG, Allen LV. 
Pharmaceutical dosage forms and drug 
deliverysystem.B.I. Waverly Pvt. Ltd, New Delhi. 
1995; 6:99-154. 
3.Atyabi F, Sharma HL, Mohammad HAH, Fell JT. 
In-vivo evaluation of a novel      gastro retentive 
formulation based on ion exchange resins. J. Control. 
Rel.1996; 42: 105-13.& Singh BN, Kim HK. Floating 
drug delivery systems: an approach to oral controlled 
drug   delivery via gastric retention. J. Control. 
Rel.2000; 63: 235-59. 
4. Ayhan Savaşer, Yalçın Özkan, and Aşkın Işımer, 
“Preparation and in vitro evaluation of sustained 
release tablet formulations of diclofenac sodium” 
Department of Pharmaceutical Technology, Gülhane 
Military Medical Academy, Etlik, 06018 Ankara, 
Turkey. October-2008. 
5.Banker GS, Anderson NR; Tablets: Lachman L, 
Lieberman HA, Kanig JL; The Theory and Practice 
of Industrial Pharmacy. 3rdedi,Varghese Publication 
House, Bombay, 1987;296-303.  
6.Banker, G.S, and Rhodes C.T., 1996, “Modern 
Pharmaceutics”, 3rd ed., Marcel Dekker, New York 
pp. 678-721 
7.Bexis s, phillis B.D, Ong j , White  J.M, Irvine R. 
J(2004-09).” Baclofen prevents MDMA-inducedrise 
in core body temperature in rats”74(1):89-96. 
8.Blume,R.W.,Davis,R.D., and Keyser, D. J.,2002, 
“Guaifenesin sustained release formulation and 
tablets”, U.S. Patent No. 6,372,252 
9.Bodmeier R, Paeratakul O. The effect of curing on 
drug release and morphological properties of 
ethylcellulose pseudolatex-coated beads. Drug Dev 
Ind Pharm 1994; 20(9): 
 
